saredutant
Sign in to saveAlso known as SR 48,968, SR 48968, SR-48,968, SR48968
Saredutant (SR-48,968) is a drug that acts as a NK2 receptor antagonist. It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Saredutant (SR-48,968) is a drug that acts as a NK2 receptor antagonist. It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.
==See also== GR-159,897 Ibodutant Nepadutant
Excerpted from Wikipedia’s “saredutant” article, available under the CC BY-SA 4.0 licence.